PreMD Reduces Staffing, Operations - FDA Appeal Still in Process

    TORONTO, Feb. 26 /CNW/ - Predictive medicine company PreMD Inc. (TSX:
PMD; today announced that it is reducing staffing and operations.
    "Over the last while we have faced significant challenges and, with the
current economic environment, we are not currently able to continue to finance
our clinical or operational activities." said Dr. Brent Norton, President and
CEO. "We will be moving to a skeleton staff and working with key executives to
explore alternatives that may allow our Company to continue to operate until
the outcomes of our FDA appeal and patent loss lawsuit are known. The timing
of our circumstances is unfortunate as our FDA appeal appears to be
progressing but without a definite time frame of knowing when we will have an
outcome. It is very regrettable that as politicians and interest groups are
calling for healthcare prediction and prevention more than ever, today we are
stuck on the FDA doorstep with our non-invasive test for predicting heart
disease, have to cancel our participation in a clinical trial for a test that
may provide early detection of colorectal cancer that is partially funded by
the US NCI, EDRN and have terminated development on a test for early breast
cancer detection when we just reported positive clinical trial results."
    PreMD's reduction plan calls for the closing of its McMaster Laboratory,
scaling back its office in Toronto, eliminating all staff and terminating
clinical programs and product licenses. In order to limit the Company's future
cash expenditures, the Company has also terminated the employment agreements
of each of the officers of the Company. However, Dr. Norton will remain as an
officer of the Company and with administrative support will continue to act on
the Company's behalf in its efforts to secure enough financing to maintain its
key intellectual property assets and continue with the FDA appeal and patent
loss lawsuit.

    About PreMD Inc.

    PreMD Inc. has rapid, non-invasive tests for the early detection of
life-threatening diseases. PreMD's cardiovascular products include PREVU(*) POC
and PREVU(*) LT, both non-invasive skin cholesterol tests. The Company's cancer
tests include ColorectAlert(TM), LungAlert(TM) and a breast cancer test.
PreMD's head office is located in Toronto, Ontario and its research and
product development facility is at McMaster University in Hamilton, Ontario.
For more information about PreMD, please visit

    This press release contains forward-looking statements. These statements
involve known and unknown risks and uncertainties, which could cause the
Company's actual results to differ materially from those in the
forward-looking statements. Such risks and uncertainties include, among
others, the successful development or marketing of the Company's products, the
competitiveness of the Company's products if successfully commercialized, the
lack of operating profit and availability of funds and resources to pursue R&D
projects, the successful and timely completion of clinical studies, product
liability, reliance on third-party manufacturers, the ability of the Company
to take advantage of business opportunities, uncertainties related to the
regulatory process, and general changes in economic conditions. In addition,
while the Company routinely obtains patents for its products and technology,
the protection offered by the Company's patents and patent applications may be
challenged, invalidated or circumvented by our competitors and there can be no
guarantee of our ability to obtain or maintain patent protection for our
products or product candidates. Investors should consult the Company's
quarterly and annual filings with the Canadian and U.S. securities commissions
for additional information on risks and uncertainties relating to the
forward-looking statements. Investors are cautioned not to rely on these
forward-looking statements. PreMD is providing this information as of the date
of this press release and does not undertake any obligation to update any
forward-looking statements contained in this press release as a result of new
information, future events or otherwise.

    %SEDAR: 00007927E          %CIK: 0001179083

For further information:

For further information: Brent Norton, President & CEO, Tel: (416)
222-3449 ext 22, Email:; Mike Evelegh, Executive V P,
Clinical & Regulatory Affairs, Tel: (905) 627-6324, Email:

Organization Profile


More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890